Management ChangeJun 2, 2026, 04:07 PM
Cue Biopharma Appoints Daniel Camardo & Viola Meehan to Board
AI Summary
Cue Biopharma announced a significant board transition, with four independent directors resigning and two new independent directors, Daniel Camardo and Viola Meehan, appointed. This strategic change aims to support the company's growth and transformation towards late clinical stage capabilities. Camardo brings extensive commercial leadership experience, including successful launches of blockbuster medicines, while Meehan offers broad expertise in strategic finance and corporate operations. The new appointments are expected to drive patient and shareholder value as the company advances its pipeline.
Key Highlights
- Cue Biopharma appointed Daniel Camardo to its board of directors.
- Cue Biopharma appointed Viola Meehan to its board of directors.
- Four independent directors (Jill Broadfoot, Peter Kiener, Frank Morich, Patrick Verheyen) resigned.
- Daniel Camardo brings over 30 years of industry experience, including CEO roles.
- Camardo contributed to successful launches of multiple blockbuster medicines ($1B+ annual sales).
- Viola Meehan brings over 30 years of experience in board and strategic finance roles.
- Board transition supports strategic growth and late clinical stage capabilities.
Price Impact
More from CUE